RE:RE:RE:RE:POSITIVE NEWSWillthethrill wrote: I really like the statement "As DIAGNOS continues to develop new algorithms and detect more illness." from the last NR. I think that as soon as the cardio is ready, Medicare will use it. And maybe Diagnos is planning to use this algorithm for allot more illnesses. I can see them using it to detect melanoma and other skin diseases as well.
The company looks to have a few things in the pipeline...the best part is they will run on CARA platform which is already FDA approved...I would think after showimg how well DR has worked...Cardio and others running on the same platform should give ADK a big advantage when it comes time to go from pipeline to market...my guess is one the big boys we wait till we get Cardio in place then takeover of ADK ...let the little guy do all the heavy lifting and approvals...imho...
CARA is a proprietary teleophthalmology platform, which includes advance retinal imaging technology and clinical grading services. Developed inhouse, the platform is a software program that uses enhanced digital images to support and identify, at an early stage, vision loss, and more specifically, diabetic retinopathy.
The company has received regulatory approvals from authorities such as US FDA “5 10 k”, Health Canada, and CE in Europe for CARA. It operates in 15 countries at different degrees of deployment, with installations in hospitals, clinics and mobile vans.
In addition to CARA, which is in the production phase and remains the key sales contributor, the company has actively been developing other healthcare-focused software tools as well, which are in different phases of development. CARDIO is another important software being tested by DIAGNOS in four countries, after CARA, and appears to have strong growth potential. A few other healthcare-focused software tools, which are
presently in the development phase, include OCT, Sleep Apnea and Alzheimer’s disease. Later...
Bob